Remove stat-awards
article thumbnail

STAT turns 8: A letter from the executive editor

STAT

Today STAT turns 8. Murrow awards. Today I have a more pointed appeal: for you to buy a STAT+ subscription. Or I express my pride over our staff being named Pulitzer or Emmy finalists, and our consecutive Polk and Edward R. Read the rest…

article thumbnail

Lotte Knudsen, who pushed Novo Nordisk into the Ozempic era, wins STAT Innovation award

STAT

Back in the 1990s, scientist Lotte Bjerre Knudsen was tasked with revitalizing a floundering program at Novo Nordisk that had been trying to harness the newly-discovered GLP-1 hormone into viable diabetes drug candidates. At the time, many of Knudsen’s bosses had already lost hope for the program.

127
127
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: How a cash-prize system that phases out patents may lower drug prices

STAT

moved a step closer to an idea he has championed for some time — awarding prizes, instead of patents, for inventing medicines. government would finance more drug research and award cash prizes to companies when they invent drugs or hit milestones. Continue to STAT+ to read the full story… T wo months ago, Sen.

138
138
article thumbnail

Listen: Is the Nobel committee evolving? Plus, preventing public health’s wiliest virus

STAT

And is the oft-criticized institution that awards the Nobel Prize each year showing signs of evolution? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Will we ever get an HIV vaccine?

Vaccines 110
article thumbnail

STAT+: Patent thickets and terminal disclaimers: How pharma blocks biosimilars from the marketplace

STAT

By doing so, a drugmaker can circumvent prohibitions on awarding more than one patent for an invention. Continue to STAT+ to read the full story… As a result, a drug company can quickly add a number of patents that can be used to protect its medicines from would-be rivals.

article thumbnail

STAT+: Roivant’s CEO is a star, but even a blockbuster deal can’t escape biotech’s black hole

STAT

It’s a subjective award, but deal-making acumen, management skills, and delivering shareholder value are important measuring sticks. Continue to STAT+ to read the full story… Gline created $5 billion from $50 million — in less than one year. Regular readers know that every December, I choose a best biopharma CEO.

111
111
article thumbnail

STAT+: ‘Learning each other’s language’: FDA, patent office seek to work together to lower drug prices

STAT

Not long after the patent was awarded, the company leveraged federally funded research and began investigating different forms of the compound, called Revlimid. Continue to STAT+ to read the full story… One expires next year and the other in 2027, well beyond the original patent expiration date.

FDA 122